Maximizing treatment benefits in type 2 diabetes by affordable oral anti diabetes agents in India

Ashok K. Das¹*, B. Krishnakumar², Ajish T. P.³, Raka Sheohare⁴, Sachin Chittawar⁵

¹Department of Endocrinology and Medicine, Pondicherry Institute of Medical Sciences, Puducherry, India
²Department of Cardiology, Government Medical College, Thiruvananthapuram, Kerala, India
³Department of Endocrinologist, Travancore Medical College, Kollam, Kerala, India
⁴Department of Diabetology, Lifeline Madhumeet Diabetes hospital, Raipur, Chhattisgarh, India
⁵Department of Endocrinology, Harmony Super Specialty Clinic, Bhopal, Madhya Pradesh, India

Received: 22 July 2021
Accepted: 18 August 2021

*Correspondence:
Dr. Ashok K. Das,
E-mail: ashokdas82@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Diabetes mellitus (DM) is a global epidemic with number of cases rising exponentially with each decade. What makes it more concerning is its association with numerous complications like cardiovascular diseases, end-stage renal disease, neuropathy, and retinopathy. In India, the management of this disease mainly involves out-of-pocket expense and contributes to catastrophic health expenditure and distress financing. Thus, the need of the hour is to make oral anti diabetes agents (OADs) affordable and accessible so that maximum number of patients can avail treatment benefits in diabetes care. This review article focuses on the currently available low cost OADs such as sulfonylureas, metformin, thiazolidinediones, alpha glucosidase inhibitors, dipeptidyl-peptidase 4 (DPP4) inhibitors and sodium-glucose co-transporter-2 (SGLT2) inhibitors explaining their efficacy and safety from recent clinical evidence and those going off patent and becoming much affordable in their generic form. This information will help family physicians make rational choices for their type 2 DM (T2DM) patients.

Keywords: Diabetes mellitus, Oral anti diabetes agents, Efficacy, Safety, Affordable therapy

INTRODUCTION

Diabetes mellitus (DM) is a global epidemic which affected an estimated 463 million persons worldwide in 2019; and is projected to reach 578 million by 2030 and 700 million by 2040.¹ The increasing prevalence of DM is attributed to a variety of factors, including the rise in the aging population, ethnicity, change in lifestyle, obesity, socioeconomic status, and urbanization.² The increasing prevalence in DM is associated with a significant increase in complications like cardiovascular diseases, end-stage renal disease, neuropathy, and retinopathy.² Notable points regarding health economics of diabetes in India are private healthcare are the predominant provider of diabetes care with government setups providing only around 20% of care, expenditure done on diabetes care is largely

Overview of mechanism of actions of the affordable OADs

Figure 1 explains the pathophysiologic abnormalities in type 2 diabetes mellitus (T2DM) and various sites of action of different affordable OADs.
Role of metformin in management of hyperglycemia and beyond

Metformin is the most common prescribed OAD in the world and shall continue to maintain its position despite of recent introduction of several new classes of oral agents for T2DM management. Metformin is effective as monotherapy and, in combination with both insulin secretagogues (sulfonylureas) and thiazolidinediones (TZDs) and may obviate the need for insulin treatment. Several fixed-dose combination pills containing metformin and other agents are available. Metformin remains a safe and effective agent for the therapy of patients with type 2 DM. It is still in most circumstances the agent of choice for first line initial therapy of the typical obese patient with T2DM and mild to moderate hyperglycemia. Reduction in mortality in people with diabetes and COVID-19 among metformin users compared to non-users are well documented.5

Metformin use significantly reduced mortality in women with obesity or T2DM in observational study from individuals hospitalized with COVID-19. This sex-specific finding is probably due to metformin reducing tumour necrosis factor alpha (TNF-alpha) in females over males. Metformin benefits in COVID-19 might be through TNF-alpha effects.6 Metformin use was associated with nearly 70% reduction in mortality in people with diabetes and COVID-19. It may provide a protective approach in this high-risk population.7 The various benefits of metformin therapy have been summarized in Table 1.

Sulfonylureas

Sulfonylureas (SUs) has been used consistently for the past six decades for T2DM treatment, having stood the test of time, considered as contemporary classic in diabetes management. There are three generations of SU. Glimepiride and gliclazide MR are usually called as modern SUs. Modern SUs differs from other conventional SUs in several aspects. It is associated with a greater efficacy, lower risk of hypoglycemia, less weight gain, good cardiovascular safety profile, pleiotropic benefits and offers optimal glycemic control in a cost-effective manner.8 Table 2 shows classification of SUs based on the generation, as conventional and modern based on hierarchy of development, and lastly, based on duration of action (short, intermediate and long-acting).

![Figure 1: Causes of hyperglycemia in type 2 diabetes mellitus and drugs used for its management.](image)

Table 1: Benefits of metformin.5,7

| Parameters                  | Benefit                                                                 |
|-----------------------------|------------------------------------------------------------------------|
| Glucose                     | Improved glycemic control (FPG 50-70 mg%, HbA1c 1.5-2%)                |
| Lipids                      | Reduced triglycerides, reduced total cholesterol, reduced LDL cholesterol, increased HDL cholesterol |
| Weight loss, no hypoglycemia| Weight reduction, low incidence of hypoglycemia or reduced serum insulin |
| Blood pressure              | Blood pressure reduction                                               |
| Atherostatic                | Increased fibrinolytic activity (reduced PAI-1 levels), reduced platelet aggregation, reduced fibrinogen levels |
| Endothelial modulator       | Improved vascular relaxation, reduced C-reactive protein               |
| Ovulation GDM, pregnancy    | Increased ovulation in PCOS, reduced gestational DM in PCOS, reduced first trimester pregnancy loss in PCOS |
| COVID-19                    | Reduction in mortality in people with diabetes and COVID-19            |

FPG-Fasting plasma glucose; HbA1c-glycated hemoglobin, LDL-low density lipoproteins, HDL-high density lipoproteins, PAI-1-plasminogen activator inhibitor-1, PCOS-polycystic ovary syndrome.
Table 2: Classification of SUs.8-10

| Classification based on generation | Molecules                                                                 |
|----------------------------------|---------------------------------------------------------------------------|
| First-generation                 | Tolbutamide, chlorpropamide                                               |
| Second-generation                | Glipizide, glibenclamide, gliclazide                                      |
| Third generation                 | Glimepiride                                                               |

| Classification based on hierarchy of development | Molecules                                                                 |
|---------------------------------------------------|---------------------------------------------------------------------------|
| Conventional                                     | Tolbutamide, glibenclamide                                                |
| Modern                                            | Glimepiride, gliclazide MR, glipizide MR                                  |

| Classification based on mechanism of action | Molecules                                                                 |
|--------------------------------------------|---------------------------------------------------------------------------|
| Short-acting                                | Tolbutamide                                                              |
| Intermediate-acting                         | Glipizide, gliclazide                                                     |
| Long acting                                 | Glibenclamide, glimepiride, glipizide MR, glazide MR                      |

**Monotherapy with modern SUs**

A study evaluated the efficacy and safety of once daily administration of glimepiride in doses of 1 mg, 4mg and 8 mg in people with type 2 diabetes mellitus. At the end of the study there was 1.2%, 1.8% and 1.9% more reduction in HbA1c levels in the glimepiride 1 mg, 4 mg and 8 mg groups respectively, compared to placebo.11 In a systematic review and meta-analysis, SU monotherapy was found to lower glycated hemoglobin (HbA1c) by 1.51% more than placebo.12 Another meta-analysis of randomized clinical trials validated the comparing the efficacy of metformin and glimepiride monotherapy, reported that glimepiride was as effective as metformin in achieving glycemic control.13

**Early combination therapy with modern SUs and metformin**

Modern SUs and metformin have a complimentary mechanism of action. Metformin with its insulin-sensitizing property facilitates insulin uptake by the peripheral tissues and enhances the glucose utilization in adipose and intestinal tissues. Modern SUs increase insulin secreting capacity of β-cells. Both together may reduce hepatic glucose overproduction.14

In a randomized, open-label, parallel group, multicenter trial, a fixed dose combination (FDC) of glimepiride plus metformin therapy provided significantly greater reduction in A1C (−1.2 versus −0.8%, p<0.0001) and fasting plasma glucose (FPG) (−35.7 versus −18.6 mg/dl, p<0.0001) compared with metformin up-titration. Furthermore, a significantly greater proportion of patients with FDC glimepiride and metformin achieved A1C <7% (74.7 versus 46.6%, p<0.0001) at the end of the study.15

**Safety profile of modern sulfonylureas**

Although modern SUs are well tolerated there is always a query among the scientific community on its safety profile in terms of beta cell dysfunction, hypoglycemia, weight gain and cardiovascular safety.16 Evidence suggests that β-cell de-differentiation, rather than cell death, is responsible for β-cell failure in T2DM. Cellular differentiation, is not a unidirectional process. In some instances, differentiation is disrupted, and beta cells revert to a less-differentiated or precursor-like state. The mechanisms which are implicated in β-cell dedifferentiation include oxidative stress, hypoxia inflammation and endoplasmic reticulum stress. In dedifferentiation, β-cells do not die; rather, they undergo metabolic and structural reconfiguration, which ultimately leads to defective insulin secretion.17 SUs has been wrongly assumed to cause beta cell death in people with T2DM and this has been clearly explained by the findings from various long-term studies like action in diabetes and vascular disease: preterax and diamicron modified release controlled evaluation (ADVANCE) trial and its ability to protect against autophagy-associated β-cell death. A recent study that evaluated the effects of exenatide, sitagliptin, and glimepiride on β-cell secretory capacity in early T2DM, indicated that it was glimepiride but not exenatide or sitagliptin, that enhanced β-cell secretory capacity.18 With the available scientific evidence it is clear that SUs are not harmful to β-cell mass or function. when used early during T2DM the modern SUs appears to improve β-cell secretory capacity.17,18

Hypoglycemia is one of the important clinical concerns associated with the use of SUs. It is more common with old generation SUs such as glibenclamide than the modern SUs. The GUIDE study conducted to evaluate the efficacy and safety of two modern SUs (gliclazide and glimepiride), reported hypoglycemia in 66% and 69% of patients treated with gliclazide and glimepiride respectively. Further, there were no episodes of hypoglycemia that required external assistance or nocturnal symptomatic episodes, indicating the safety of modern SUs.19 The strategic timing of antiretroviral treatment (START) study also reported a comparable incidence of hypoglycemia in patients treated with glimepiride and sitagliptin.20 Another meta-analysis reported lower rates of severe hypoglycemia with gliclazide compared to other antidiabetic drugs.21
In the management of T2DM, treatment with SUs has been always linked to weight gain. It is important to note that treatment of T2DM with several other medications including thiazolidinediones and insulin are also associated with weight gain. Weight gain associated with SUs may not be bad, in fact it could be considered as an indicator for reduction in glucotoxicity. Weight gain with sulfonylureas could be attributed to enhanced utilization of ingested glucose and subsequent lowering in glycosuria. There are multiple clinical evidence available now to explain that the modern SUs have a weight neutral profile. Once daily administration of glimepiride was associated with weight neutralizing/reducing effect over a period of 1.5 years. In recent CAROLINA trial, after an initial weight gain, there was a decrease in weight in people receiving glimepiride.

Modern SUs (glimepiride and gliclazide MR) are associated with a lower risk of all-cause and CV-related mortality compared to conventional SUs in T2DM patients. The results of the recent CAROLINA demonstrated no difference in the composite of time to cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke between the linagliptin and glimepiride groups. In a study of gliclazide MR, of 4.3 years follow-up with people with diabetes co-treated with perindopril-indapamide combination, was associated with 15% reduction in major macro- and micro-vascular events, 28% reduction in risk of all renal events and 18% reduction in all-cause death. In a meta-analysis of 47 randomized controlled trials (RCTs) involving 37,650 type 2 diabetes mellitus patients of 52-week duration, the association between modern SUs and all-cause and cardiovascular mortality (CV) was assessed. The analysis revealed that Modern SUs are not associated with an increased risk of myocardial infarction, all-cause and cardiovascular mortality. Figure 2 explains the various pleiotropic benefits of modern SUs.

**Thiazolidinediones**

Thiazolidinediones (TZDs) are the only OAD agents that function predominantly as insulin sensitizers in peripheral and hepatic tissues by binding to and activating nuclear peroxisome proliferator-activated receptor γ (PPARγ) expressed in those tissues. In India, pioglitazone is used at 15-30 mg/day mostly with metformin and sulfonylureas. Pioglitazone comes with a great efficacy parameter. TZDs have been constantly under the authority scrutiny for their cardiovascular safety. PROactive study, pioglitazone lowered the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in T2DM patients with at risk of macrovascular events along with improvements in HbA1c, triglycerides, LDL, and HDL levels. Pioglitazone had been linked with a possible increased risk of bladder cancer, possibly in a dose-and time-dependent manner. However data from a retrospective study in India involving T2DM patients found no evidence of bladder cancer in any of the group, including patients with age >60 years, duration of diabetes >10 years, and uncontrolled diabetes. Beneficial effects and possible risks have been enlisted in Table 3.

**Alpha glucosidase inhibitors**

These agents delay the absorption of consumed carbohydrates by competitively inhibiting the α-glucosidase enzymes at the enterocyte brush border. This inhibition delays the digestion of starch and sucrose and maintains levels of postprandial blood glucose excursions. In India, acarbose and voglibose are the most used drugs in this class. The action of these agents is independent of insulin action and hence are devoid of hypoglycemic adverse effects. They are used ideally used to target the post prandial hyperglycemia. In India, this class of drug is usually used either as combination with Metformin or combination with metformin and sulfonylureas. Table 4 enlists efficacy and safety studies of metformin, glimepiride and voglibose combination either as FDC or as triple therapy.

**DPP4 inhibitors**

DPP4 inhibitors enhance circulating concentrations of active GLP-1 and gastric intestinal polypeptide (GIP). These incretins stimulate insulin secretion, suppresses glucagon synthesis, lower hepatic glucoseogenesis, and slow gastric emptying. Their major effect is the regulation of insulin and glucagon secretion; they are weight neutral. Teneligliptin is the first of its kind low-cost gliptin approved in India, which made gliptin therapy available for everyone. Teneligliptin is effective as single dose of 20 mg and shown renal safety, recent studies TREAT-INDIA 1 and TREAT-INDIA 2 both have established cardiovascular safety. Recently the patent expiry of vildagliptin had seen multiple generic versions with affordable cost of therapy and is available as single or as FDC with metformin. Sitagliptin is in line for patent expiry and likely to have generic versions available in upcoming years. DPP-4 inhibitors are efficient in improving glycaemia both as monotherapy and as add-on to metformin, sulfonylurea and TZDs in patients with inadequate glycemic control. Table 5 provides a list of recent trials with teneligliptin.

**SGLT2 inhibitors**

They provide insulin-independent glucose-lowering by blocking glucose reabsorption in the proximal renal tubule. The capacity of tubular cells to reabsorb glucose is reduced by SGLT2 inhibitors leading to increased urinary glucose excretion and consequently, correction of the hyperglycemia. Remogliflozin is the recently approved SGLT2 inhibitor in India which comes with an affordable cost of therapy. The antidiabetic agent was shown to be effective, safe, and well-tolerated in a pivotal study. Remogliflozin demonstrated non-inferiority to existing SGLT2 inhibitor, namely dapagliflozin. The drug demonstrated comparable results in glycemic, non-glycemic, and safety parameters as compared to...
A well-known drug in this class is dapagliflozin, recent developments of expiry of the patent of dapagliflozin there are multiple generic brands are to be available in affordable cost in upcoming days. The most common AEs involving this class of OADs are genital mycotic infections and euglycemic ketosis in wrongly selected patient (type 1 diabetes, LADA). To summarize, Table 6 provides an overview of the efficacy, CV safety and side effects of various classes of OADs.

Table 3: Benefits and risks associated with pioglitazone therapy.\textsuperscript{32}

| Benefit                                      | Risk                                      |
|----------------------------------------------|-------------------------------------------|
| Potent, durable HbA1c reduction              | Fat weight gain – but decreases visceral, hepatic and muscle fat content |
| Low risk of hypoglycaemia                   | Fluid retention/heart failure             |
| Improves insulin resistance                 | Bone fractures (distal long bones, trauma related) |
| Improves beta-cell function                 | Bladder cancer (not established)          |
| Prevents IGT progression to T2DM            |                                           |
| Improves cardiovascular risk factors (↑HDL, ↓triglyceride, ↓blood pressure, ↓inflammation) |                                           |
| Reduces microalbuminuria                    |                                           |
| Decreases cardiovascular events in high-risk diabetic patients (PROactive, IRIS, meta-analysis) |                                           |
| Reduces cardiovascular events in diabetic patients with chronic kidney disease |                                           |
| Improves endothelial dysfunction            |                                           |
| Improves NASH/NAFLD                         |                                           |

Table 4: Efficacy and safety studies of metformin, glimepiride and voglibose combination either as FDC or as triple therapy.\textsuperscript{34}

| Author            | Drug dosage                                      | Efficacy and safety results                                                                 |
|-------------------|--------------------------------------------------|---------------------------------------------------------------------------------------------|
| Hari et al 2014   | Metformin 500 mg (SR#) + glimepiride 1/2 mg + voglibose 0.2 mg OD. (FDC) | Significant reduction in FPG (181±10.2 mg/dl to 116±2.97 mg/dl; p<0.0001), PPG (239±11.2 mg/dl to 140±4.42 mg/dl; p<0.0004), and HbA1c (9.07±0.346 to 6.51±0.129; p<0.0001). All of the patients tolerated the drug and no adverse events were reported. |
| Faruqui et al 2016| Metformin 500 mg (SR#) + glimepiride 0.5 mg + voglibose 0.2 mg BD. (FDC) | Significant decrease in HbA1c value 10.6±1.3 versus 6.6±0.4 (p<0.0001), FPG levels 208.33 mg/dl versus 118.06 (p<0.0001), and PPHG levels 360.14 mg/dl versus 168.36, (p<0.0001). None of the patients complained about adverse events including nausea, vomiting and headache at the given doses of medication. |

Continued.
**Table 5: Summary of teneligliptin trials.**

| Author              | Study design                                      | Dose                                      | Baseline values | Results                                                                 |
|---------------------|--------------------------------------------------|-------------------------------------------|-----------------|-------------------------------------------------------------------------|
| Eto et al 2012      | Randomized, double blinded, placebo controlled, parallel study (n=99) | Teneligliptin- 10 mg (n=34), 20 mg (n=33) | HbA1c-8.3% FPG-1621 mg/dl | DPP4 inhibition rate at 24 hours was 66.9±4.17%                          |
| Kadowaki et al 2018 | Interim analysis (n=11,627)                      | Teneligliptin- 20 mg/day                 | HbA1c-7.57% FPG-147.6 mg/dl | Overall ADRs; 3.46% and most common ADRs were hypoglycemia (0.32%) and constipation: 0.27% |
| Kim et al 2016      | Phase 3, randomized, double blind, non-inferiority study (n=201) | Teneligliptin- 20 mg/day (n=103), sitagliptin- 100 mg/day (n=98) | HbA1c-8.11% | At 24 weeks, reduction from baseline in HbA1c : teneligliptin: -1.03±0.10%, sitagliptin: -1.02-0.10% |
| Kadowaki et al 2013 | Double blinded, placebo controlled, parallel group study (n=204) | Teneligliptin-20 mg (n=103)               | HbA1c-8.1% FPG-150.7 mg/dl | Significant reduction in HbA1c and FPG were observed with teneligliptin treatment |
| Hashikata et al 2016| Single-center, pilot-study (n=27)                | Teneligliptin-20 mg, 40 mg                | HbA1c-7.5% LVEF -63.7% E-13.4 | Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes |

**Table 6: Overview of affordable OADs.**

| Class of OADs | Efficacy | Effect on weight | CV effects | Key side effects | Summary |
|---------------|----------|------------------|------------|------------------|---------|
| Biguanides: metformin | High | Weight loss/weight neutral | Beneficial CV effects, reduces LDL-C and increases HDL-C | Lactic acidosis | First-line drug therapy of choice for T2DM |
| Modern sulfonylureas: glimepiride, gliclazide XR | High | Lesser weight gain/versus older Sus | Glimepiride had shown similar CV safety to DPP4i | Hypoglycemia and weight gain | Second line drug |
| TZDs: pioglitazone | High | Weight gain | Increased risk of MI, CHF, increased | Weight gain, CV outcomes | Second line drug, to be avoided in patients with or at risk for heart failure |

Continued.
CONCLUSION

With number of cases of T2DM rising rapidly in India, treatment benefits and incurring expenditure need to be balanced out carefully. The selection of the OADs to be responsible patient centered approach. Metformin and modern SUs combination is the most used combination in India and are time tested affordable, available, accessible drug combination in offering optimal glycemic control, pleiotropic benefits, with CV safety profile in a cost-effective manner. Other low-cost drugs belonging to the class of AGIs and TZDs are available to be used appropriately as 2nd or 3rd line agents. Recently available low cost DPP4 inhibitors and SGLT2 inhibitors are welcome in the affordable T2DM treatment armamentarium and to be used wherever appropriate.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. IDF DIABETES ATLAS. Ninth edition 2019. International diabetes federation. Available at: https://www.diabetesatlas.org/en/resources/. Accessed on 25 May 2021.
2. Thibault V, Bélanger M, LeBlanc E, Babin L, Halpiane S, Greene B, et al. Factors that could explain the increasing prevalence of type 2 diabetes among adults in a Canadian province: a critical review and analysis. Diabetol Metab Syndr. 2016;8(1):71.
3. Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. WJD. 2016;7(17):354.
4. Singla R, Bindra J, Singla A, Gupta Y, Kalra S. Drug prescription patterns and cost analysis of diabetes therapy in India: Audit of an endocrine practice. Indian J Endocr Metab. 2019;23:40-5.
5. Joshi SR. Metformin: old wine in new bottle-evolving technology and therapy in diabetes. J Assoc Physicians India. 2005;53:963-72.
6. Bramante C, Ingraham N, Murray T. Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19. medRxiv. 2020.
7. Crouse A, Grimes T, Li P. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. medRxiv. 2020.
8. Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocr Metab. 2015;19:577-96.
9. Sola D, Rossi L, Schianca GP. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840-8.
10. Costello RA, Shivkumar A. Sulfonylureas. In: StatPearl. Treasure Island (FL): StatPearls Publishing. 2020.
11. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care. 1996;19:849-56.
12. Hirst JA, Farmer AJ, Dyrar A. Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis. Diabetologia. 2013;56(5):973-84.
13. Zhu H, Zhu S, Zhang X, Guo Y, Shi Y, Chen Z, et al. Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: Meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2013;5:70.
14. Kalra S, Bahendeka S, Sahay R. Consensus recommendations on sulfonylurea and sulfonylurea
combinations in the management of Type 2 diabetes mellitus – International task force. Indian J Endocr Metab. 2018;22:132-57.

15. Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, et al. Efficacy of glimepiride/metformin fixed-dose combination vs. metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig. 2014;5:701-8.

16. Shunmugavelu M, Shah T, Vijaya Kumar G. Myths and Facts About Glimepiride. JAPI. 2019;24-6.

17. Dor Y, Glaser B. β-cell dedifferentiation and type 2 diabetes. N Engl J Med. 2013;368:572-3.

18. Gudipaty L, Rosenfeld NK, Fuller CS. Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes. Diabetes Care. 2014;37:2451-8.

19. Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535-42.

20. Devarajan TV, Venkataraman S, Kandasamy N. Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study. Indian J Endocrinol Metab. 2017;21(5):745-50.

21. Landman GWD, de Bock GH, van Hateren KJJ, van Dijk PR, Groenier KH, Gans ROB, et al. Safety and Efficacy of Gliclazide as Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials. Letizia Hribal M, editor. PLoS ONE. 2014;9(2):82880.

22. Green JB, Feinglos MN. Are sulfonylureas passé? Curr Diab Rep. 2006;6(5):373-7.

23. Weitgasser R, Lechleitner M, Lugner A, Klingler A. Effects of glimepiride on HbA1c (1c) and body weight in Type 2 diabetes: Results of a 1.5-year follow-up study. Diabetes Res Clin Pract. 2003;61:13-9.

24. Rosenstock J, Kahn SE, Johansen OE. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes The CAROLINA Randomized Clinical Trial. JAMA. 2019;322:1155-66.

25. Kalra S, Ghosh S, Das AK, Nair T. Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials; expert opinion from an international panel. Indian Heart J. 2020;72(1):7-13.

26. John M, Kalra S, Nair T. Modern sulfonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy? Indian Heart J. 2020;72(4):312-5.

27. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009;32:2068-74.

28. Rados DV, Pinto LC, Remonti LR. The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. PLOS Medicine. 2016;3:43-51.

29. Dormandy JA, Charbonnel B, Eckland DJ, PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005;366(9493):1279-89.

30. Lewis JD, Ferrara A, Peng T, Heddderson M, Bilker WB, Quesenberry CP, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916-22.

31. Pai SA, Kshirsagar NA. Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report. Indian J Med Res. 2016;14:672-81.

32. DeFronzo RA, Inzucchi S, Abdul-Ghani M. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16(2):133-43.

33. Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest. 1994;24(3):3-10.

34. Glycemic pentad Glycemic Pentad Forum. Consensus statement. 2017. Available at: https://www.japi.org/s2c4a4/glycemic-pentad. Accessed on 12 February 2021.

35. Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs. 2013;18:245-58.

36. Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Teneligliptin in management of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2016;9:251-60.

37. Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S. Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study). Diabetes Metab Syndr Obes. 2016;9:347-53.

38. Ghosh S, Tiwaskar M, Chawla R, Jaggi S, Asirvatham A, Panikar V. Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA). Diabetes Ther. 2020;11(10):2257-68.

39. Diabetes drug price to halve as patent expires; cheaper versions expected soon. Available at: https://www.businesstoday.in/sectors/pharma/diabetes-drug-price-to-halve-as-patent-expires-cheaper-versions-expected-soon/story/391768.html. Accessed on 13 February 2021.

40. Ahren B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes. 2010;3:31-41.
41. Chowdhury S, Chadha M, Ghosh S. Indian expert review on use of teneligliptin in patients with diabetes and its safety and efficacy (INTENSE). JAPI. 2021;69.
42. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5-14.
43. Markham A. Remogliflozin etabonate: First global approval. Drugs. 2019;79:1157-61.
44. Mohan V, Mithal A, Joshi SR, Aravind SR, Chowdhury S. Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy. Drug Des Devel Ther. 2020;14:2487-501.
45. Aggarwal A, Wadhwa R, Kapoor D. High prevalence of genital mycotic infections with sodium-glucose co-transporter 2 inhibitors among Indian patients with type 2 diabetes. Indian J Endocr Metab. 2019;23:9-13.
46. Hurren KM, Dunham MW. Are thiazolidinediones a preferred drug treatment for type 2 diabetes? Expert Opin Pharmacother. 2021;22(2):131-3.
47. Meneghini LF, Orozco-Beltran D, Khunti K. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab. 2011;96(11):3337-53.
48. Coleman RL, Scott CAB, Lang Z. Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. Cardiovasc Diabetol. 2019;18(1):135.
49. Dabhi AS, Bhatt NR, Shah MJ. Voglibose: an alpha glucosidase inhibitor. J Clin Diagn Res. 2013;7(12):3023-7.

Cite this article as: Das AK, Krishnakumar B, Ajish TP, Sheohare R, Chittawar S. Maximizing treatment benefits in type 2 diabetes by affordable oral anti diabetes agents in India. Int J Adv Med 2021;8:1618-26.

Provide full name of authors: First name-Middle name initial-Last name

Present citation of figure 1

Present reference citation in number in superscript in highlighted tables